Canada markets open in 3 hours 9 minutes

Marinus Pharmaceuticals, Inc. (MRNS.MX)

Mexico - Mexico Delayed Price. Currency in MXN
Add to watchlist
124.000.00 (0.00%)
At close: 10:22AM CST
Currency in MXN

Valuation Measures4

Market Cap (intraday) 1.24B
Enterprise Value 544.00M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)13.16
Price/Book (mrq)7.43
Enterprise Value/Revenue 1.05
Enterprise Value/EBITDA -615.80

Trading Information

Stock Price History

Beta (5Y Monthly) 1.11
52-Week Change 3-32.65%
S&P500 52-Week Change 323.20%
52 Week High 3184.12
52 Week Low 3124.00
50-Day Moving Average 3124.00
200-Day Moving Average 3127.44

Share Statistics

Avg Vol (3 month) 3N/A
Avg Vol (10 day) 3N/A
Shares Outstanding 554.93M
Implied Shares Outstanding 671.44M
Float 837.71M
% Held by Insiders 11.13%
% Held by Institutions 1104.51%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:4
Last Split Date 3Sept 23, 2020

Financial Highlights

Currency in USD.

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Mar 31, 2024

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-466.48%

Management Effectiveness

Return on Assets (ttm)-46.11%
Return on Equity (ttm)-423.43%

Income Statement

Revenue (ttm)28.29M
Revenue Per Share (ttm)0.51
Quarterly Revenue Growth (yoy)-26.00%
Gross Profit (ttm)N/A
EBITDA -129.39M
Net Income Avi to Common (ttm)-145.34M
Diluted EPS (ttm)-48.40
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)113.25M
Total Cash Per Share (mrq)2.06
Total Debt (mrq)112.51M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)3.07
Book Value Per Share (mrq)-0.30

Cash Flow Statement

Operating Cash Flow (ttm)-113.98M
Levered Free Cash Flow (ttm)-63.64M